Table 1.
ncRNAs influence TIE via regulating tumor cells death signals by targeting death-related genes
| ncRNAs | Target genes and function | Type of cancer | Refs. |
|---|---|---|---|
| miR-195, 24-2 and 365 | Downregulate Bcl-2 and promote apoptosis of tumor cells | Breast cancer | 37 |
| miR-125b, miR-106a | Upregulate Bcl-2 and inhibit apoptosis of tumor cells | Leukemia, Breast cancer | 38,39 |
| miR-133a | Downregulates Bcl-xL and McL-1, and promotes apoptosis of tumor cells | Osteosarcoma | 40 |
| lncRNA HELH | Upregulates Bcl-xL, which mediated by miR-939, and inhibits apoptosis of tumor cells | Colorectal Cancer | 288 |
| lncRNA ASNR | Inhibits the degradation of Bcl-2 by targeting AUF1, and inhibits apoptosis of tumor cells | Stomach cancer, Colon cancer, Liver cancer, Lung cancer | 289 |
| lncRNA OPI5-AS1 | Upregulates Bcl-2, which mediated by miR-448, and inhibits apoptosis of tumor cells | Lung adenocarcinoma | 290 |
| miR-125a-5p, 26a, 193b, 363, 101, 29a, 29b, 106a, 181b, 302b and 320 | Downregulate MCL-1 and promote apoptosis of tumor cells | Colon cancer, Breast cancer, lymphomas, Multiple myeloma, Ovarian cancer, Acute myeloid leukemia, HCC, Cervical cancer | 291–301 |
| miR-205,133b and 218 | upregulate MCL-1 and inhibit apoptosis of tumor cells | Lung cancer | 302,303 |
| miR-25 | Downregulates DR4 and promotes apoptosis of tumor cells | Cholangiocarcinoma | 41 |
| miR-133b | Increases the sensitivity of tumor cells to TRAIL- mediated apoptosis by targeting FAIM | PC-3 and HeLa cell lines | 304 |
| miR-942 | Reduces the sensitivity of tumor cells to TRAIL-mediated apoptosis by targeting ISG12a | Hepatocellular carcinoma, Gastric cancer | 305 |
| miR-221 and 222 | Reduce the sensitivity to TRAIL-mediated apoptosis by targeting p27kip1 | NSCLC | 306 |
| miR-212 | Reduces the sensitivity of tumor cells to TRAIL-induced apoptosis by targeting PED | NSCLC, Liver cancer | 307 |
| miR-130a | Enhances the sensitivity of tumor cells to TRAIL-induced apoptosis by targeting MET | Lung cancer | 308 |
| miR-145, 216, 182 and 96 | Reduce the sensitivity of tumor cells to TRAIL-induced apoptosis by targeting DR4/5, FADD | Breast cancer | 309 |
| miR-200c | Reduces the sensitivity of tumor cells to FAS-mediated apoptosis by targeting FAP-1 | Human kidney clear cell cancer | 310 |
| miR-21 | Downregulates FASL and inhibits apoptosis of tumor cells | Pancreatic cancer | 311 |
| miR-590 and 20a | Downregulate FASL and FAS, and inhibit apoptosis of tumor cells | Osteosarcoma | 312 |
| miR-128a | Downregulates FAS and inhibits apoptosis of tumor cells | Acute T-cell leukemia | 313 |
| lncRNA MAGI2-AS3 | Upregulates FASL and FAS, and inhibits apoptosis of tumor cells | Breast cancer | 42 |
| miR-23a | Downregulates granzyme B and inhibits CTL-mediated death | Lung cancer | 43 |
| miR-27a | Downregulates granzyme B and perforin, inhibits CTL-mediated death | Colorectal cancer cell line sw260 | 314 |
AUF1 ARE/poly (U)-binding/degradation factor 1, FAIM Fas apoptosis inhibitory molecule, ISG12a interferon stimulated gene 12a, PED PED/PEA-15, FADD Fas-associated death domain, FAP-1 Fas-associated phosphatase-1, NSCLC non-small cell lung cancer